Discuss Sermorelin on glp1chat
Join the forum to discuss research with other members.
At a glance
Sermorelin copies part of the signal that tells the pituitary to release growth hormone. Studies measure the hormone response, which depends on how well the pituitary and the rest of the hormone system work.
The pituitary acts as a hormone-producing control center. Sermorelin sends it a growth-hormone-releasing message, after which researchers can measure growth hormone and IGF-1. It can only call on a system capable of responding; it is not growth hormone itself. Findings in people being evaluated for a hormone problem do not automatically describe an effect in healthy adults.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The cited context includes pediatric endocrine studies and other research. Results from growth hormone deficiency cannot establish a general adult anti-aging effect.[1][2][1]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Sermorelin.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
| Week | Daily Dose (µg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 200 µg | 12 units (0.12 mL) |
| Weeks 3–4 | 300 µg | 18 units (0.18 mL) |
| Weeks 5–6 | 400 µg | 24 units (0.24 mL) |
| Weeks 7–8 | 500 µg | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously at bedtime. Bedtime administration is strongly recommended because endogenous GH secretion peaks during sleep[1]. This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units ≥10 for better accuracy. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once‑daily nightly regimen.
- Goal: Stimulate endogenous pituitary GH release to support physiologic IGF‑1 levels and anabolic processes[1][2].
- Schedule: Daily subcutaneous injections at bedtime for 3–6 months (pediatric trials ran 6–12 months; adult use is off‑label)[1].
- Dose Range: 200–500 µg daily (adult research range; pediatric: 30 µg/kg nightly)[1][2].
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized refrigerated; reconstituted refrigerated and used within 10–14 days[3].
Suggested nightly titration approach for adult off‑label use.
- Start: 200 µg nightly at bedtime; increase by ~100 µg every 1–2 weeks as tolerated.
- Target: 300–500 µg nightly by Weeks 5–8 (adjust based on IGF‑1 response).
- Frequency: Once per day (subcutaneous, preferably before sleep)[1].
- Cycle Length: 3–6 months typical for adult research use; pediatric trials ran 6–12 months[1].
- Timing: Bedtime administration leverages natural nocturnal GH pulse; rotate injection sites systematically[5].
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; gently swirl to dissolve (do not shake vigorously)[2].
- Label with reconstitution date and refrigerate at 2–8 °C (36–46 °F), protected from light[2][3].
- Wipe vial stopper with alcohol before each use; use a new sterile needle and syringe for each injection[2].
Storage Instructions
Proper storage preserves peptide potency and sterility.
- Lyophilized: Store at 2–8 °C (36–46 °F) in dry, dark conditions[2]. Do not freeze dry powder; check expiration date.
- Reconstituted: Refrigerate at 2–8 °C (36–46 °F)[3]; do not freeze mixed solution[3]. Use within 10–14 days when using bacteriostatic water (multi‑dose vial).
- Allow vials to reach room temperature before reconstituting to aid dissolution; inspect solution before each use (should be clear and colorless)[2].
- Always use aseptic technique: swab stopper with alcohol before each draw; use new sterile needle and syringe per injection[2].
Materials & quantity planning
Source materials checklist · 5 mg
Plan based on an 8–week daily protocol with gradual titration (56 injections total).
-
Peptide Vials (Sermorelin, 5 mg each):
- 8 weeks (total ~19.6 mg consumed): 4 vials (20 mg total)
- 12 weeks (similar daily range): 6–7 vials
- Tip: Have 1 extra vial as backup in case of spillage or loss.
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes (recommend 1 × 100‑count box)
- 12 weeks: 84 syringes (1 × 100‑count box)
- Preferred: 0.3–0.5 mL size with 28G–31G needle, 5/16″ to 1/2″ length for subcutaneous use.
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 12 weeks (7 vials): 21 mL → 3 × 10 mL bottles
- Contains benzyl alcohol preservative; do not use if allergic.
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- Sharps Container: One puncture‑proof disposal container for used needles (sufficient for 56+ syringes).
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 07
Public health resource
NCBI Bookshelf — Best practices for parenteral injections: aseptic technique, preparation, administration guidelines (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.